Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve 1. Audited financial results for ....
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bal Pharma Ltd has informed BSE that its Board of Directors will meet on Thursday, 29 May 2025. Key agenda items include approval of audited standalone and consolidated financial results for Q4 and the full financial year ended 31 March 2025, along with the Directors' and Auditors' reports. The Board will also consider recommending a dividend, if any, for FY25. Additionally, it will appoint Internal Auditors, Cost Auditors for FY 2025-26, and Secretarial Auditors for a five-year term subject to shareholder approval. The trading window for designated persons remains closed from 1 April 2025 until 31 May 2025.
This is a routine pre-results intimation with no new financial data disclosed. Investors should watch for the actual audited results and any dividend declaration on 29 May, which could influence short-term stock sentiment.